Processa Pharmaceuticals, Inc.
PCSANasdaq
$2.31
↑ +3.1%Jul 17 close · end-of-day
Price
1Y↓ -57.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.1M
Enterprise Value
$4.4M
P/E
—
P/S
—
P/B
2.4
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$13.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
512.5%
ROIC
-1345.4%
Debt / Equity
—
Net Cash
$1.7M
Return 1Y
-56.5%
Company profile
Processa Pharmaceuticals, Inc. focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the. treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company was incorporated in 2011 and is based in Hanover, Maryland.
- CEO
- David Young
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Maryland
- Website
- processapharmaceuticals.com
Management & directors
- Ng George KChief Executive Officer
- Guy WendyChief Administrative Officer
- Lin PatrickChief Business - Strategy Off
- Skibsted RussellChief Financial Officer
- Young DavidPres. Research & Development
- Bigora SianChief Development Officer
Roles derived from SEC Form 4 filings.
Earnings
PCSA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.29↓ -83.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$15.1M | -$12.1M | -$27.5M | -$11.5M | -$12.1M | -$14.0M |
| Net income | -$14.4M | -$11.4M | -$27.4M | -$11.1M | -$11.8M | $13.6M |
| Diluted EPS | — | — | -$34.05 | -$8.48 | -$96.78 | -$10.36 |
| Operating cash flow | -$3.1M | -$8.7M | -$9.6M | -$8.1M | -$11.2M | -$11.4M |
| Free cash flow | — | — | — | -$8.1M | -$11.2M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.1M | -$3.4M | -$2.7M | -$2.8M | -$4.0M | -$3.5M | -$3.7M | -$3.3M |
| Net income | -$3.0M | -$3.4M | -$2.7M | -$2.8M | -$3.9M | -$3.4M | $23.8M | -$3.4M |
| Diluted EPS | -$1.01 | -$1.03 | -$93.63 | -$7.58 | -$0.25 | -$0.07 | -$2.46 | -$1.29 |
| Operating cash flow | -$3.3M | -$3.6M | -$2.2M | -$2.7M | -$2.3M | -$3.5M | -$2.9M | -$3.6M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jan 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Ng George K· Chief Executive Officer | Buy | 3,057 | $1.93 | $5,900.01 | filing |
| 2026-06-30 | SKIBSTED RUSSELL· Chief Financial Officer | Buy | 3,277 | $1.93 | $6,324.61 | filing |
| 2026-06-30 | Young David· Pres. Research & Development | Buy | 2,531 | $1.93 | $4,884.83 | filing |
| 2026-06-30 | Guy Wendy· Chief Administrative Officer | Buy | 2,436 | $1.93 | $4,701.48 | filing |
| 2026-06-30 | Lin Patrick· Chief Business - Strategy Off | Buy | 2,106 | $1.93 | $4,064.58 | filing |
| 2026-06-26 | Neal James R | Option exercise | 203 | — | — | filing |
| 2026-06-26 | Yorke Justin W | Option exercise | 203 | — | — | filing |
| 2026-06-26 | Pannu Geraldine | Option exercise | 203 | — | — | filing |
| 2026-06-26 | Baluch Khoso | Option exercise | 203 | — | — | filing |
| 2026-06-15 | SKIBSTED RUSSELL· Chief Financial Officer | Buy | 2,654 | $2.22 | $5,891.88 | filing |
| 2026-06-15 | Ng George K· Chief Executive Officer | Buy | 2,465 | $2.22 | $5,472.30 | filing |
| 2026-06-15 | Guy Wendy· Chief Administrative Officer | Buy | 2,118 | $2.22 | $4,701.96 | filing |
| 2026-06-15 | Young David· Pres. Research & Development | Buy | 2,067 | $2.22 | $4,588.74 | filing |
| 2026-06-15 | Lin Patrick· Chief Business - Strategy Off | Buy | 1,831 | $2.22 | $4,064.82 | filing |
| 2026-05-29 | SKIBSTED RUSSELL· Chief Financial Officer | Buy | 2,292 | $2.57 | $5,890.44 | filing |
| 2026-05-29 | Ng George K· Chief Executive Officer | Buy | 2,129 | $2.57 | $5,471.53 | filing |
| 2026-05-29 | Guy Wendy· Chief Administrative Officer | Buy | 1,829 | $2.57 | $4,700.53 | filing |
| 2026-05-29 | Young David· Pres. Research & Development | Buy | 1,786 | $2.57 | $4,590.02 | filing |
| 2026-05-29 | Lin Patrick· Chief Business - Strategy Off | Buy | 1,582 | $2.57 | $4,065.74 | filing |
| 2026-05-15 | SKIBSTED RUSSELL· Chief Financial Officer | Buy | 1,984 | $2.97 | $5,892.48 | filing |
| 2026-05-15 | Ng George K· Chief Executive Officer | Buy | 1,843 | $2.97 | $5,473.71 | filing |
| 2026-05-15 | Guy Wendy· Chief Administrative Officer | Buy | 1,583 | $2.97 | $4,701.51 | filing |
| 2026-05-15 | Young David· Pres. Research & Development | Buy | 1,545 | $2.97 | $4,588.65 | filing |
| 2026-05-15 | Lin Patrick· Chief Business - Strategy Off | Buy | 1,369 | $2.97 | $4,065.93 | filing |
| 2026-04-30 | SKIBSTED RUSSELL· Chief Financial Officer | Buy | 2,190 | $2.69 | $5,891.10 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.